News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,330 Results
Type
Article (44234)
Company Profile (308)
Press Release (681788)
Multimedia
Podcasts (93)
Webinars (12)
Section
Business (212359)
Career Advice (2184)
Deals (37099)
Drug Delivery (115)
Drug Development (84227)
Employer Resources (177)
FDA (16724)
Job Trends (15585)
News (359978)
Policy (34448)
Tag
Academia (2632)
Accelerated approval (5)
Adcomms (26)
Allergies (91)
Alliances (52077)
ALS (94)
Alzheimer's disease (1413)
Antibody-drug conjugate (ADC) (143)
Approvals (16714)
Artificial intelligence (276)
Autoimmune disease (26)
Automation (16)
Bankruptcy (377)
Best Places to Work (11842)
BIOSECURE Act (21)
Biosimilars (117)
Biotechnology (193)
Bladder cancer (78)
Brain cancer (29)
Breast cancer (285)
Cancer (2337)
Cardiovascular disease (192)
Career advice (1820)
Career pathing (33)
CAR-T (158)
Cell therapy (440)
Cervical cancer (19)
Clinical research (68470)
Collaboration (878)
Compensation (544)
Complete response letters (28)
COVID-19 (2686)
CRISPR (46)
C-suite (252)
Cystic fibrosis (103)
Data (2230)
Decentralized trials (2)
Denatured (29)
Depression (48)
Diabetes (285)
Diagnostics (6485)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (125)
Drug pricing (120)
Drug shortages (31)
Duchenne muscular dystrophy (96)
Earnings (88777)
Editorial (40)
Employer branding (21)
Employer resources (152)
Events (116513)
Executive appointments (746)
FDA (18010)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (769)
Gene editing (114)
Generative AI (24)
Gene therapy (325)
GLP-1 (796)
Government (4613)
Grass and pollen (5)
Guidances (65)
Healthcare (19151)
Huntington's disease (24)
IgA nephropathy (30)
Immunology and inflammation (134)
Indications (30)
Infectious disease (2839)
Inflammatory bowel disease (142)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (340)
IPO (16950)
IRA (48)
Job creations (4163)
Job search strategy (1555)
Kidney cancer (11)
Labor market (38)
Layoffs (508)
Leadership (23)
Legal (8531)
Liver cancer (76)
Lung cancer (331)
Lymphoma (157)
Machine learning (7)
Management (61)
Manufacturing (329)
MASH (72)
Medical device (13512)
Medtech (13517)
Mergers & acquisitions (20697)
Metabolic disorders (754)
Multiple sclerosis (85)
NASH (20)
Neurodegenerative disease (100)
Neuropsychiatric disorders (33)
Neuroscience (1986)
NextGen: Class of 2025 (6727)
Non-profit (4556)
Now hiring (39)
Obesity (409)
Opinion (249)
Ovarian cancer (77)
Pain (98)
Pancreatic cancer (84)
Parkinson's disease (156)
Partnered (21)
Patents (244)
Patient recruitment (111)
Peanut (50)
People (59815)
Pharmaceutical (98)
Pharmacy benefit managers (21)
Phase I (21339)
Phase II (30079)
Phase III (22531)
Pipeline (1227)
Policy (160)
Postmarket research (2685)
Preclinical (9024)
Press Release (68)
Prostate cancer (109)
Psychedelics (31)
Radiopharmaceuticals (255)
Rare diseases (408)
Real estate (6367)
Recruiting (67)
Regulatory (23498)
Reports (46)
Research institute (2393)
Resumes & cover letters (370)
Rett syndrome (5)
RNA editing (5)
RSV (48)
Schizophrenia (78)
Series A (133)
Series B (87)
Service/supplier (14)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (153)
Sponsored (30)
Startups (3794)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (45)
The Weekly (62)
Vaccines (725)
Venture capitalists (41)
Weight loss (289)
Women's health (36)
Worklife (17)
Date
Today (187)
Last 7 days (891)
Last 30 days (2716)
Last 365 days (33798)
2025 (11012)
2024 (36148)
2023 (40930)
2022 (52113)
2021 (56674)
2020 (55110)
2019 (47822)
2018 (36140)
2017 (33570)
2016 (33172)
2015 (39008)
2014 (32960)
2013 (28077)
2012 (30166)
2011 (30871)
2010 (28889)
Location
Africa (809)
Alabama (53)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (41713)
Australia (6626)
California (6181)
Canada (2031)
China (549)
Colorado (269)
Connecticut (276)
Delaware (152)
Europe (89469)
Florida (928)
Georgia (206)
Idaho (57)
Illinois (553)
India (26)
Indiana (322)
Iowa (11)
Japan (167)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (914)
Massachusetts (4652)
Michigan (222)
Minnesota (394)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (64)
New Hampshire (63)
New Jersey (1757)
New Mexico (31)
New York (1758)
North Carolina (1020)
North Dakota (8)
Northern California (2696)
Ohio (207)
Oklahoma (14)
Oregon (40)
Pennsylvania (1388)
Puerto Rico (13)
Rhode Island (33)
South America (1184)
South Carolina (23)
South Dakota (1)
Southern California (2311)
Tennessee (102)
Texas (921)
United States (23494)
Utah (184)
Virginia (154)
Washington D.C. (62)
Washington State (561)
West Virginia (3)
Wisconsin (57)
726,330 Results for "lantern pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
March 28, 2025
·
16 min read
Press Releases
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
March 20, 2025
·
5 min read
Lone Star Bio
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced that the Japan Patent Office has issued a Certificate of Patent for patent application no. 2021-513267 / registration no. 7489966 directed to Lantern Pharma’s drug candidate LP-284.
June 12, 2024
·
8 min read
Press Releases
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
February 19, 2025
·
8 min read
Business
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning platform with multiple clinical-stage drug programs, announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024.
May 9, 2024
·
20 min read
Press Releases
Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
January 27, 2025
·
9 min read
Lone Star Bio
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
Lantern Pharma Inc. announced an important milestone in its antibody-drug conjugate program.
February 15, 2024
·
9 min read
Business
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
Lantern Pharma Inc. today announced that it will host its first quarter 2024 financial results webcast on Thursday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.
May 2, 2024
·
6 min read
News
Lantern Pharma to Host & Participate in Two Public Webinars During October
October 21, 2024
·
8 min read
Drug Development
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
Lantern Pharma Inc. announced today that – the company has received regulatory approval to expand its Harmonic™ trial, a Phase 2 clinical study evaluating LP-300 in non-small cell lung cancer.
April 22, 2024
·
10 min read
1 of 72,633
Next
